CVS Health (NYSE:CVS) Given New $107.00 Price Target at UBS Group

CVS Health (NYSE:CVS) had its price objective decreased by investment analysts at UBS Group from $118.00 to $107.00 in a report released on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the pharmacy operator’s stock. UBS Group‘s target price would suggest a potential upside of 31.74% from the stock’s previous close.

Several other brokerages have also issued reports on CVS. Piper Sandler set a $112.00 price objective on shares of CVS Health in a report on Wednesday, September 9th. Robert W. Baird set a $107.00 target price on shares of CVS Health in a research note on Thursday, August 6th. Wall Street Zen cut shares of CVS Health from a “strong-buy” rating to a “buy” rating in a research report on Monday, October 19th. Argus boosted their price target on shares of CVS Health from $104.00 to $114.00 and gave the company a “buy” rating in a research note on Wednesday, August 19th. Finally, Raymond James Financial restated an “outperform” rating and issued a $120.00 price objective on shares of CVS Health in a report on Wednesday. Twenty-two investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $108.96.

CVS Health Trading Up 1.6%

CVS opened at $81.22 on Thursday. The stock has a market capitalization of $103.88 billion, a PE ratio of 9.46, a P/E/G ratio of 0.73 and a beta of 0.58. CVS Health has a one year low of $69.51 and a one year high of $110.68. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.66 and a current ratio of 0.85. The business’s 50 day moving average price is $90.56 and its 200 day moving average price is $88.87.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, November 4th. The pharmacy operator reported $2.09 EPS for the quarter, beating the consensus estimate of $1.65 by $0.44. The business had revenue of $108.40 billion for the quarter, compared to analyst estimates of $104.72 billion. CVS Health had a return on equity of 13.65% and a net margin of 2.62%. The company’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.60 EPS. As a group, equities research analysts expect that CVS Health will post 8.20 EPS for the current year.

Institutional Trading of CVS Health

Several hedge funds have recently added to or reduced their stakes in the company. Elevation Wealth Partners LLC raised its holdings in shares of CVS Health by 41.8% in the 2nd quarter. Elevation Wealth Partners LLC now owns 356 shares of the pharmacy operator’s stock valued at $37,000 after purchasing an additional 105 shares in the last quarter. HBW Advisory Services LLC lifted its position in shares of CVS Health by 3.5% during the 3rd quarter. HBW Advisory Services LLC now owns 3,408 shares of the pharmacy operator’s stock worth $292,000 after purchasing an additional 115 shares during the last quarter. Apella Capital LLC grew its stake in shares of CVS Health by 1.7% during the second quarter. Apella Capital LLC now owns 6,940 shares of the pharmacy operator’s stock worth $724,000 after purchasing an additional 117 shares in the last quarter. Wellington Altus USA Inc. grew its stake in shares of CVS Health by 13.3% during the second quarter. Wellington Altus USA Inc. now owns 1,025 shares of the pharmacy operator’s stock worth $106,000 after purchasing an additional 120 shares in the last quarter. Finally, Childress Capital Advisors LLC increased its holdings in CVS Health by 3.9% in the third quarter. Childress Capital Advisors LLC now owns 3,497 shares of the pharmacy operator’s stock valued at $300,000 after buying an additional 131 shares during the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS reported third-quarter adjusted EPS of $2.09, beating the $1.65 consensus, while revenue rose 5.4% to $108.4 billion. Management also raised its 2026 earnings outlook, supporting the view that operating performance is improving. CVS Health third-quarter results
• Neutral Sentiment: Leerink Partners and Barclays lowered their price targets but kept Outperform and Overweight ratings, respectively—signaling continued confidence in potential upside while reflecting greater uncertainty. Leerink Partners price target
• Negative Sentiment: CVS plans to separate its retail pharmacy business from its insurance and pharmacy-benefit operations, creating two public companies by 2028. Investors have reacted negatively to the surprise announcement and lack of detail on separation costs, debt allocation, dividends, and the businesses’ standalone finances. CVS breakup announcement
• Negative Sentiment: The split reverses CVS’s strategy of combining pharmacies, Aetna, and Caremark, raising questions about whether the breakup will improve results or simply add execution costs and uncertainty. Commentary also cautions that separating the businesses may not make prescriptions more affordable. Analysis of CVS’s merger strategy
• Negative Sentiment: AM Best placed ratings for Aetna insurance subsidiaries under review with developing implications, adding to uncertainty as the corporate structure changes. AM Best ratings review

About CVS Health

CVS Health Corporation (NYSE: CVS) is a diversified health care company that provides pharmacy, insurance and health services in the United States. Its businesses serve consumers, employers, health plans and health care providers through pharmacies, benefit programs, insurance coverage and clinical care services.

The company’s Pharmacy Services segment, led by CVS Caremark, manages prescription drug benefits for employers, insurers and government programs. CVS Pharmacy operates retail pharmacies and health-focused stores that dispense prescriptions and offer over-the-counter products, health and wellness merchandise, immunizations and related services.